However, cells that do express high levels of BCL-XL proteins, such as senescent cells with anti-apoptotic phenotype (dual positive for p16/BCL-XL) and also tumor cells with higher BCL-XL, could potentially be eliminated by ABT-263. This evidence concerns the gene CDKN2A and neoplasm.